What does biotechnology — goodwill acquired mean?

This metric tracks the amount of goodwill added to the balance sheet specifically from acquisitions completed within the biotechnology segment during the current reporting period. It reflects the company's inorganic growth strategy and the capital deployed to expand its product portfolio or market reach.

Bio-Techne TECH Biotechnology — Goodwill Acquired

Discontinued — last reported Q3 '18

Similar metrics at other companies

DHRBiotechnology — Goodwill

$23B+3.1%

HSICGlobal Technology — Goodwill Acquired

$6.5M—

LHBiopharma Laboratory Services — Goodwill acquired, excluding measurement period adjustments

$0—

ROP

ROPTechnology Enabled Products — Goodwill acquired

$0-100%

WAT

WATBiosciences — Goodwill

$3.8B—

TYLPlatform Technologies — Goodwill, Acquired During Period

$0—

Other financials

Income statement

See full

Revenue$311.4M-1.5%

Gross profit$208.3M-2.9%

Operating income$75.5M+95.0%

Net income$51.0M+126%

EPS (diluted)$0.32+129%

Balance sheet

See full

Cash & equivalents$209.8M+49.2%

Total debt$290.3M-31.4%

Total equity$2.1B+3.3%

Total assets$2.6B-3.5%

Cash flow

See full

Operating cash flow$86.7M+111%

CapEx$9.1M-10.2%

Free cash flow$77.6M+150%

Valuation

See full

Market cap$9.07B-11.8%

Enterprise value$9.15B-13.6%

P/E60.6×+13.6×

P/S7.5×-1.0×

Profitability

See full

Gross margin65%-0.8pp

Operating margin14.2%-7.9pp

Net margin10.9%-6.7pp

FCF margin22.3%+4.0pp

Returns & leverage

See full

Return on equity6.5%-3.9pp

Debt / equity0.1×-0.1×

Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.

The official record: Bio-Techne’s 10-Q, filed May 9, 2018, on SEC EDGAR. View the filing →

Questions, answered.

What does biotechnology — goodwill acquired mean?: This metric tracks the amount of goodwill added to the balance sheet specifically from acquisitions completed within the biotechnology segment during the current reporting period. It reflects the company's inorganic growth strategy and the capital deployed to expand its product portfolio or market reach.